<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650129</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1352</org_study_id>
    <nct_id>NCT01650129</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>An Open-labelled, Randomised, Parallel Group, Multicentre, Safety and Efficacy Study of NN-X14Mix50 (BIAsp50) in a Twice Daily Regimen in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of this trial is to investigate the safety and
      efficacy of biphasic insulin aspart (BIAsp) 50 (NN-X14Mix50) compared with biphasic human
      insulin (BHI) 50 in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2000</start_date>
  <completion_date type="Actual">October 18, 2001</completion_date>
  <primary_completion_date type="Actual">October 18, 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated haemoglobin A1c (HbA1c)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse event(s)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemic episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin antibodies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin doses</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BIAsp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BHI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner</description>
    <arm_group_label>BIAsp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic human insulin 50</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner</description>
    <arm_group_label>BHI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  Subjects with insulin treated for at least 24 weeks

          -  HbA1c maximum 11.0%

          -  Body mass index (BMI) below 30.0 kg/m^2

          -  Patients who have the skill of self-injection of insulin, and are able and willing to
             perform self-monitoring blood glucose (SMBG) and are able to take measures against
             hypoglycaemic episodes

        Exclusion Criteria:

          -  Recurrent severe hypoglycaemia

          -  Subjects with proliferative retinopathy or preproliferative retinopathy diagnosed
             within the last 12 weeks, or receiving photocoagulation therapy within the last one
             year

          -  Impaired hepatic function

          -  Impaired renal function

          -  Cardiac diseases

          -  Uncontrolled hypertension

          -  Subjects with history of severe allergic or severe hypersensitive reactions

          -  Total daily insulin dose at least 100 IU

          -  Treatment with oral hypoglycaemic agentsvwithin the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

